CTNNB1 (β-catenin) mutations in NSCLC: clinicogenomic characteristics, prognostic value and implications for therapy
Glaser, M.; von Levetzow, C.; Rasokat, A.; Prang, D.; Nogova, L.; Woempner, C.; Schmitz, J.; Bitter, E.; Terjung, I.; Eisert, A.; Fischer, R.; John, F.; Michels, S.; Riedel, R.; Ruge, L.; Scharpenseel, H.; Schulte, W.; Sommerwerck, U.; Siebolts, U.; Merkelbach-Bruse, S.; Buettner, R.; Wolf, J.; Scheffler, M.
Show abstract
Although mutations in CTNNB1 have long been associated with cancer, their impact in patients with non-small cell lung cancer (NSCLC) is not well understood. Beyond a potential role in the acquired resistance setting of EGFR-mutant NSCLC, little is known about the clinical and molecular characteristics of NSCLC patients harboring these mutations. Here, we identify 302/15,688 (1.9%) NSCLC patients with CTNNB1 mutations. These mutations frequently co-occur with EGFR and KRAS mutations and are associated with a favorable prognosis (mOS, 45.8 months overall; 19.7 months KRASmut). Patients benefit significantly from immune-checkpoint-blockade, but non-intuitively,PD-L1 TPS [≥]50%(4/6 treated with monotherapy) survive the shortest. We show that patients with proposed CTNNB1 resistance mutations to EGFR-directed therapy have significantly shorter mOS when treated with targeted therapy, compared to non-resistant CTNNB1 mutations. This study highlights unique clinicogenomic features and the nuanced impact of CTNNB1 mutations on therapeutic outcomes.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.